Luminex Co. (NASDAQ:LMNX) Receives Average Rating of “Hold” from Brokerages

Luminex Co. (NASDAQ:LMNX) has received a consensus rating of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $30.00.

Several equities analysts have recently weighed in on the stock. BidaskClub downgraded shares of Luminex from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. ValuEngine downgraded shares of Luminex from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 11th. Zacks Investment Research upgraded shares of Luminex from a “sell” rating to a “hold” rating in a research note on Tuesday, March 19th. Finally, William Blair reiterated a “market perform” rating on shares of Luminex in a research note on Tuesday, May 7th.

Several hedge funds have recently added to or reduced their stakes in LMNX. Norges Bank bought a new position in shares of Luminex in the fourth quarter valued at approximately $22,764,000. Bessemer Group Inc. boosted its position in shares of Luminex by 63.0% in the fourth quarter. Bessemer Group Inc. now owns 866,888 shares of the medical instruments supplier’s stock valued at $20,034,000 after acquiring an additional 335,037 shares during the period. Elk Creek Partners LLC bought a new position in shares of Luminex in the first quarter valued at approximately $7,105,000. Kennedy Capital Management Inc. bought a new position in shares of Luminex in the first quarter valued at approximately $6,162,000. Finally, Marshall Wace LLP boosted its position in shares of Luminex by 3,439.2% in the first quarter. Marshall Wace LLP now owns 195,680 shares of the medical instruments supplier’s stock valued at $4,503,000 after acquiring an additional 190,151 shares during the period. Institutional investors own 84.71% of the company’s stock.

LMNX opened at $21.31 on Monday. The stock has a market capitalization of $977.36 million, a PE ratio of 44.40, a price-to-earnings-growth ratio of 20.12 and a beta of 0.81. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.99 and a quick ratio of 2.70. Luminex has a twelve month low of $20.24 and a twelve month high of $35.37.

Luminex (NASDAQ:LMNX) last posted its earnings results on Monday, May 6th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.14). The business had revenue of $82.41 million during the quarter, compared to analysts’ expectations of $83.10 million. Luminex had a return on equity of 1.62% and a net margin of 2.55%. Luminex’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.30 EPS. On average, equities research analysts anticipate that Luminex will post 0.07 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Thursday, June 20th will be given a $0.06 dividend. The ex-dividend date is Wednesday, June 19th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.13%. Luminex’s dividend payout ratio (DPR) is currently 50.00%.

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.

Featured Article: Investing strategies using the yield curve

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.